Begin main content

Combination Agents for Multiple Myeloma: Comparative Clinical Effectiveness

Last updated: March 18, 2019
Project Number: RB1317-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the comparative clinical effectiveness cyclophosphamide + bortezomib + dexamethasone (CyBorD) versus bortezomib + melphalan + prednisone (VMP) for newly diagnosed patients with multiple myeloma where there is no intent for stem cell transplantation?
  2. What is the comparative clinical effectiveness cyclophosphamide + bortezomib + dexamethasone (CyBorD) versus lenalidomide + dexamethasone (RD) for newly diagnosed patients with multiple myeloma where there is no intent for stem cell transplantation?

Key Message

One non-randomized study was indentified regarding the comparative clinical effectiveness of CyBorD versus VMP in newly diagnosed patients with multiple myeloma with no eligiblity for stem cell transplantation.Additionally, no relevant health technology assessments, systematic reviews, meta-analyses and randomized controlled trials were identified regarding the comparative clinical effectiveness of CyBorD to VMP or RD.